IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3205
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$615M
T. Andrew Crockett
KalVista Pharmaceuticals, Inc. discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME) products.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$KALV KalVista Pharmaceuticals, Inc. | 42 | 19 | 44 | 66 | - | - | -1131.2% | -56.6% | 91.0% | -2275.5% | -2326.9% | - | 0.0% | 1900.0x | $615M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
KalVista Pharmaceuticals, Inc. (KALV) receives a "Reduce" rating with a composite score of 42.4/100. It ranks #3205 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for KALV.
View All RatingsROE proxy -1131.2% (sector -1.9%)
GM 91% vs sector 44%, OM -2276% vs sector 3%
Capital turnover N/A, R&D intensity 1083.0%
Rev growth N/A, 11yr history
Interest coverage -9.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate KalVista Pharmaceuticals, Inc. (KALV) as a Reduce with a composite score of 42.4/100 at a current price of $15.77. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
KalVista Pharmaceuticals, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 42.4/100 places it at rank #3205 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 91% signal strong pricing power.
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Leverage of 1900% D/E amplifies downside risk.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
KalVista Pharmaceuticals, Inc. represents a reduce based on multi-factor quantitative performance.
KalVista Pharmaceuticals, Inc. receives a Reduce rating from our analysis, with a composite score of 42.4/100 and 2 out of 5 stars, ranking #3205 out of 7,333 stocks. KALV's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
KalVista Pharmaceuticals, Inc. registers a weak quality score of just 19/100, indicating significant profitability challenges. The company reports a return on equity of -1131.2% (sector avg: -1.9%), gross margins of 91.0% (sector avg: 44.1%), net margins of -2326.9% (sector avg: 1.0%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 44/100, KALV appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 46.27x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
KalVista Pharmaceuticals, Inc.'s investment score of 20/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -56.6% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
KALV demonstrates moderate momentum with a score of 66/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of 0.69 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
KALV shows good financial stability with a score of 65/100. Key stability metrics include a beta of 0.69 and a debt-to-equity ratio of 1900.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
KalVista Pharmaceuticals, Inc.'s short interest score of 19/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 1900.00x), small-cap liquidity risk. At $615M (small-cap), KALV carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
KalVista Pharmaceuticals, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3205 of 7,333 overall (56th percentile). Key comparisons include ROE of -1131.2% trailing the -1.9% sector median and operating margins of -2275.5% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While KALV currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (19) would have the largest impact on the composite score.
ROE 59436% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 107% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 90759% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
U.S. stock futures advanced on Friday as investors awaited the December jobs report and the Supreme Court's ruling on Trump's tariffs. Major indices showed modest gains with SPY and QQQ trading higher in premarket. Key movers included General Motors facing EV investment losses, Tilray surging on earnings beats, Offerpad jumping on Trump's housing proposal, and Rio Tinto declining amid merger talks with Glencore.
FRAMINGHAM, Mass. & SALISBURY, England, February 18, 2026--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY® (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema (HAE) attacks in adolescents aged 12 years and older.1
FRAMINGHAM, Mass. & SALISBURY, England, February 12, 2026--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia, Pennsylvania from February 27–March 2, 2026.
FRAMINGHAM, Mass. & SALISBURY, England, February 03, 2026--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted six newly-hired employees inducement options to purchase an aggregate of 96,750 shares of KalVista common stock on February 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common sto
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is placed twelfth on our list. TheFly reported on January 29 that TD Cowen analyst Stacy Ku raised its price target on KALV to $35 from $30 and maintained a Buy rating. The adjustment followed […]